Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs Placebo in Children with ADHD
NCT00546910Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine with Placebo (2 arms). Primary endpoints: Change From Baseline Computer-based Continuous Performance Test Hyperactivity Q-scores at 8 weeks, Change From Baseline Computer-based Continuous Performance Test Inattention Q-scores at 8 weeks and 2 more. Started Oct 2007; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00546910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546910.